OverviewSuggest Edit

Jazz Pharmaceuticals is an international biopharmaceutical company, focused on identifying, developing and commercializing products for neurology and psychiatry. The Company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning.

TypePublic
Founded2003
HQDublin 4, IE
Websitejazzpharma.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Feb 2021)1,620
Revenue (FY, 2020)$2.4 B(+10%)
Share Price (Mar 2021)$168.8
Cybersecurity ratingBMore

Key People/Management at Jazz Pharmaceuticals

Finbar Larkin

Finbar Larkin

Senior Vice President, Technical Operations
Bruce C. Cozadd

Bruce C. Cozadd

Chairman and Chief Executive Officer
Heidi Manna

Heidi Manna

Senior Vice President and Chief Human Resources Officer
Paul L. Berns

Paul L. Berns

Director
Renée Galá

Renée Galá

Executive Vice President and Chief Financial Officer
Patrick G. Enright

Patrick G. Enright

Director
Show more

Jazz Pharmaceuticals Office Locations

Jazz Pharmaceuticals has offices in Dublin 4, Palo Alto, Philadelphia, Mississauga and in 6 other locations
Dublin 4, IE (HQ)
Waterloo Rd, Ballsbridge
Mississauga, CA
602-4080 Confederation Pkwy
Vancouver, CA
887 Great Northern Way #450
Lyon, FR
84 Quai Charles de Gaulle
München, DE
Grillparzerstraße 18
Villa Guardia, IT
Piazza XX Settembre, 2
Show all (11)

Jazz Pharmaceuticals Financials and Metrics

Jazz Pharmaceuticals Revenue

Jazz Pharmaceuticals's revenue was reported to be $2.36 b in FY, 2020
USD

Revenue (FY, 2020)

2.4b

Net income (FY, 2020)

238.6m

EBIT (FY, 2020)

378.1m

Market capitalization (1-Mar-2021)

9.5b

Closing stock price (1-Mar-2021)

168.8

Cash (31-Dec-2020)

1.1b

EV

10.7b
Jazz Pharmaceuticals's current market capitalization is $9.5 b.
USDQ2, 2011

Financial Leverage

1.9 x
Show all financial metrics

Jazz Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
CavionAugust 13, 2019$312.50 m

Jazz Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Jazz Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Jazz Pharmaceuticals Online and Social Media Presence

Embed Graph

Jazz Pharmaceuticals News and Updates

Jazz Pharmaceuticals Completes Submission of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia

DUBLIN, Feb. 16, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for Xywav™ (calcium, magnesium,...

Jazz Pharmaceuticals to Buy Pot-Drug Maker for $7.2 Billion

Jazz Pharmaceuticals to Buy GW for $7.2 Billion in Cash, Stock

Jazz Pharmaceuticals to acquire GW Pharma for $7.2 billion in cash and stock

Jazz Pharmaceuticals Plc said Wednesday it has agreed to acquire GW Pharmaceuticals Plc in a cash-and-stock deal valued at $7.2 billion. Under the terms of the deal, Jazz Pharma will pay $200 per share in cash and $20 in stock for each share owned, or a premium of about 50% over GW's closing price…

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of...

Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line

DUBLIN, Dec. 3, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, randomized, controlled study evaluating Zepzelca™ (lurbinectedin) in combination with doxorubicin...

Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors

DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jennifer Cook and Mark D. Smith, M.D. have been appointed to the Company's Board of Directors, effective December 1, 2020. "We are excited to welcome two industry leaders to the Board whose...
Show more

Jazz Pharmaceuticals Blogs

Jazz Pharmaceuticals Announces Participation at Cowen 41st Annual Healthcare Conference

DUBLIN , Feb. 23, 2021 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Cowen 41st Annual Healthcare conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company and a

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results

Highly Effective Operational Execution Drove Record Total Revenues Total Revenues Increased 9% to $2.36 Billion in 2020 2021 Full Year Total Revenue Guidance of $2.55 Billion to $2.70 Billion Zepzelca and Xywav Launches in the U.S. Continue to Exceed Expectations JZP-458 BLA Submission Initiated

Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference

Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference Content Import Wed, 02/17/2021 - 16:08 Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference February 17, 2021 …

Jazz Pharmaceuticals to Report 2020 Fourth Quarter Financial Results on February 23, 2021

DUBLIN , Feb. 9, 2021 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 fourth quarter and full year financial results on Tuesday, February 23, 2021 , after the close of the financial markets.  Company management will host a live audio webcast

Jazz Pharmaceuticals Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference

DUBLIN , Jan. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 39 th Annual J.P. Morgan Healthcare Conference . Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company

Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Application to be reviewed under FDA's Oncology Center of Excellence Real-Time Oncology Review pilot program DUBLIN , Dec. 21, 2020 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has initiated the submission of a Biologics License Application (BLA) to the
Show more

Jazz Pharmaceuticals Frequently Asked Questions

  • When was Jazz Pharmaceuticals founded?

    Jazz Pharmaceuticals was founded in 2003.

  • Who are Jazz Pharmaceuticals key executives?

    Jazz Pharmaceuticals's key executives are Finbar Larkin, Bruce C. Cozadd and Heidi Manna.

  • How many employees does Jazz Pharmaceuticals have?

    Jazz Pharmaceuticals has 1,620 employees.

  • What is Jazz Pharmaceuticals revenue?

    Latest Jazz Pharmaceuticals annual revenue is $2.4 b.

  • What is Jazz Pharmaceuticals revenue per employee?

    Latest Jazz Pharmaceuticals revenue per employee is $1.5 m.

  • Who are Jazz Pharmaceuticals competitors?

    Competitors of Jazz Pharmaceuticals include Alexza Pharmaceuticals, Consort Medical and Hikma Pharmaceuticals.

  • Where is Jazz Pharmaceuticals headquarters?

    Jazz Pharmaceuticals headquarters is located at Waterloo Rd, Ballsbridge, Dublin 4.

  • Where are Jazz Pharmaceuticals offices?

    Jazz Pharmaceuticals has offices in Dublin 4, Palo Alto, Philadelphia, Mississauga and in 6 other locations.

  • How many offices does Jazz Pharmaceuticals have?

    Jazz Pharmaceuticals has 11 offices.